インフォショップ ホームへ 株式会社グローバルインフォメーション
サイトマップ
ホーム
営業品目
委託調査
調査会社・出版社一覧
カタログ一覧
会社概要
お問い合わせ
RSSフィード
医薬品
その他のカテゴリ

商品カタログ

医療／バイオの調査資料販 MEDINFO.JP

バイオシミラー特集
バイオシミラー特集ページ バイオシミラーに関連したレポートを紹介致します。

Global Pharmaceuticals Research & Manufacturing 公式サイト

Translational Cancer Medicine 公式サイト

Global Healthcare Congress 2009 公式サイト

BioMedical Asia 2009 公式サイト

China 2009 Pharmaceutical R&D Summit 公式サイト

Drug Discovery & Development of Innovative Therapeutics Japan 2009 公式サイト

Drug Discovery & Development of Innovative Therapeutics 2009 公式サイト
English Korean Chinese
ホーム > カテゴリ > 医薬品 >
【 英文市場調査報告書 】

児童期／思春期における情緒・行動障害の治療薬市場

Emotional and Behavioral Disorders in Children and Adolescents

商品コード : 32698 BCC Research
出版日 : 2005/09
発行 : BCC Research
電話でのお問い合わせ
価格情報
概要 原文目次
※この商品は英文にてご提供いたします。

INTRODUCTION



The emotional and behavioral disorder drug market is changing as a result of the heightened awareness of these diseases in young children and adolescents and the use of drugs dedicated to controlling these problems. The key objective now is safe use and correct diagnosis. The drugs previously used had many side effects, the principal one being suicidal tendencies. Now the market is moving towards drugs that are safer to use. However, much remains to be done.

Many companies are doing research on drugs with fewer side effects and by the end of the decade, it is expected that more of them will be on the market. Efforts are underway to perform clinical trials to prove the safety of these drugs for children. These currently still are considered as "off label" uses.

Available alternatives and preferences for various drugs have made the industry acutely aware of related issues and economic characteristics. This timely BCC study looks at almost all the drug markets affected by these factors. It discusses the strengths and weaknesses of drugs being used for children, and whose safety still has not been established by regulatory authorities. Also examined are the demographics of drug use as divided by preschoolers and other age groups. In addition, the report looks at worldwide sales by region.

SCOPE OF STUDY



The report contains:

An overview of the behavioral and emotional disorders in children and adolescents
Sales figures for the following categories of drugs: benzodiazepines, mood stabilizers, antipsychotics, SSRIs, tricyclic antidepressants, CNS stimulants and nonstimulants
Market projections on their worldwide use to 2010
Drug categorizations by disorder with sales figures for each
Profiles of the companies selling these products
Discussion of factors affecting markets as a result of regulatory issues.
METHODOLOGY

A comprehensive literature and patent search was conducted. Literature included technical newsletters and journals, as well as many other sources. Data was collected through interviews with, and mail from various analytical, chemical and pharmaceutical companies. This data was compiled, and projections were based on such estimates as the current number of end users, potential end users, likely unit prices, rates of consumption and market trends.

INFORMATION SOURCES



BCC surveyed a large number of companies to obtain data for this study. Included were manufacturers and end users of orthopedic products. Information was obtained from these industries, and officials and physicians were interviewed. Newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts were consulted. Exhaustive investigations of databases by key terminology were done. In addition, data was compiled from current financial and trade information, and government sources.

ABOUT THE AUTHOR



Shalini Shahani holds a Masters degree in Pharmaceutical Chemistry. Among the research topics she has covered are: Studies on Compounds of Potential and Pharmaceutical Interest from Ibuprofen and 2-Naphthyl Acetic acid. Shahani was awarded a Gold medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are "Reagents of Chromatography," "Spectroscopy, an Enduring Market" and "Advanced Drug Delivery Systems."

Table of Contents

  • INTRODUCTION
      • STUDY OBJECTIVES
      • REASONS FOR DOING THIS STUDY
      • CONTRIBUTIONS OF THE STUDY
      • SCOPE OF THE STUDY
      • METHODOLOGY
      • INFORMATION SOURCES
      • ABOUT THE AUTHOR
      • RELATED BCC REPORTS
      • BCC ONLINE SERVICES
      • DISCLAIMER
  • SUMMARY
    • Summary Table: WORLDWIDE SALES OF DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Summary Figure: WORLDWIDE SALES OF DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • OVERVIEW
      • DEFINITIONS OF EMOTIONAL AND/OR BEHAVIOR DISORDERS
        • DEFINITIONS OF EMOTIONAL AND/OR・CONTINUED)
      • TERMINOLOGY
      • CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS
    • Table 1 DSM CLASSIFICATIONS* OF EMOTIONAL AND BEHAVIORAL DISORDERS
    • Table 2 CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS (AS DONE FOR THIS REPORT)
  • CAUSES OF EMOTIONAL AND BEHAVIOR DISORDERS
      • BIOLOGICAL FACTORS
        • PSYCHOPHYSIOLOGICAL AND GENETIC INFLUENCES
        • NEUROLOGICAL DYSREGULATION
      • ENVIRONMENTAL FACTORS
        • SCHOOL-RELATED FACTORS
        • PARENT PSYCHOLOGICAL FACTORS
        • FAMILIAL CONTRIBUTIONS
          • Divorce, Marital Distress and Violence
          • Family Adversity and Insularity
          • Parent-child Interactions
          • Other Family Characteristics
      • CHARACTERISTICS OF STUDENTS WITH BEHAVIOR DISORDERS
        • INTELLIGENCE AND ACHIEVEMENT
          • Social Skills and Interpersonal Relationships
          • Antisocial Behavior
          • Withdrawn Behavior
        • MANIFESTATIONS OF BEHAVIOR DISORDERS
  • TYPES OF DISORDERS
      • ANXIETY DISORDERS
        • TYPES OF ANXIETY DISORDERS
        • CAUSES
        • SYMPTOMS AND TREATMENT
          • Psychological Treatments
          • Psychopharmacological Treatments
          • Environmental Treatments
      • SEVERE DEPRESSION
        • CAUSES
        • SYMPTOMS AND TREATMENT
          • Symptoms and Treatment (Continued)
      • BIPOLAR DISORDER
        • SYMPTOMS AND TREATMENT
          • Symptoms and Treatment (Continued)
      • ATTENTION DEFICIT HYPERACTIVITY DISORDER
        • SYMPTOMS AND TREATMENT
      • AUTISM
        • SYMPTOMS AND TREATMENT
      • SCHIZOPHRENIA
        • SYMPTOMS AND TREATMENT
      • LEARNING DISORDERS
        • SYMPTOMS AND TREATMENT
        • CAUSES
      • CONDUCT DISORDER
        • SYMPTOMS AND TREATMENT
      • EATING DISORDERS
        • SYMPTOMS AND TREATMENTS
  • DRUG CLASSIFICATION
      • CLASSIFICATION BASED ON MECHANISM OF ACTION
        • BENZODIAZEPINES
    • Table 3 BENZODIAZEPINES
        • SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
    • Table 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
        • TRICYCLIC ANTIDEPRESSANTS
    • Table 5 TRICYCLIC ANTIDEPRESSANTS
        • ANTIHISTAMINES
    • Table 6 ANTIHISTAMINES
        • MAJOR TRANQUILIZERS OR NEUROLEPTICS
    • Table 7 MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS
        • MOOD STABILIZERS
    • Table 8 MOOD STABILIZERS
        • CNS STIMULANTS
    • Table 9 CNS STMULANTS
        • NONSTIMULANTS
    • Table 10 NONSTMULANTS
        • ATYPICAL ANTIPSYCHOTICS
    • Table 11 ATYPICAL ANTIPSYCHOTICS
      • CLASSIFICATION BASED ON THERAPEUTIC CATEGORY
        • ANTIANXIETY DRUGS
    • Table 12 DRUGS USED FOR ANTIANXIETY DISORDERS
    • Table 12 (CONTINUED)
          • Clorazepate
          • Chlordiazepoxide
          • Chlorpromazine
          • Clonezepam
          • Diazepam
          • Doxipine
          • Fluoxetine Hydrochloride
          • Fluphenazine
          • Fluvoxamine Maleate
          • Haloperidol
          • Hydroxyzine
          • Nortriptyline
          • Oxazepam
          • Sertraline Hydrochloride
          • Thioridazine
          • Thioxanthene
          • Trifluperazine
        • SEVERE DEPRESSION DRUGS
    • Table 13 DRUGS USED FOR SEVERE DEPRESSION
          • Amitryptyline
          • Fluoxetine Hydrochloride
          • Impramine
          • Sertraline Hydrochloride
        • BIPOLAR DISORDER DRUGS
    • Table 14 DRUGS USED FOR BIPOLAR DISORDER
          • Lithium
          • Divalproex
          • Carbamazepine
        • ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUGS
    • Table 15 DRUGS USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER
          • Amphetamines
          • Dextroamphetamine
          • Methylphenidate
          • Pemoline
          • Atomoxetine Hydrochloride
        • AUTISTIC DISORDER DRUGS
    • Table 16 DRUGS USED FOR AUTISTIC DISORDER TREATMENT
          • Risperidone
        • SCHIZOPHRENIA DRUGS
    • Table 17 DRUGS USED FOR SCHIZOPHRENIA
  • SAFETY, EFFICACY AND REGULATION
      • SAFETY AND EFFICACY
        • SAFETY AND EFFICACY (CONTINUED)
    • Table 18 LABELLED USE AND APPROVED AGE FOR AGENTS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS
      • REGULATORY ASPECTS
        • REGULATORY ASPECTS (CONTINUED)
        • REGULATORY ASPECTS (CONTINUED)
    • Table 19 DRUGS RECEIVING A BOXED WARNING, OTHER PRODUCT LABELING CHANGES, AND A MEDICATION GUIDE PERTAINING TO PEDIATRIC SUICIDAL TENDENCIES
        • DRUG APPROVALS
    • Table 20 DEVICES AND IMPLANTS APPROVED BY THE FDA 2000-APRIL 2005
  • INDUSTRY STRUCTURE
      • BEHAVIOR AND EMOTIONAL DISORDER DRUG INDUSTRY MARKET BY COMPANY
        • ANTIANXIETY
    • Table 21 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
    • Figure 1 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
          • Antidepressants
    • Table 22 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
    • Figure 2 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
          • Bipolar Disorders
    • Table 23 MARKET SHARES OF MANUFACTURERS PRODUCING DRUGS FOR BIPOLAR DISORDER TREATMENT, 2004 (%)
    • Figure 3 MARKET SHARES OF MANUFACTURERS PRODUCING BIPOLAR DISORDER DRUGS, 2004 (%)
          • ADHD Disorders
    • Table 24 MARKET SHARES OF MANUFACTURERS PRODUCING ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
    • Figure 4 MARKET SHARES OF MANUFACTURERS OF ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
          • Autistic Disorders
    • Table 25 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%)
    • Figure 5 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%)
          • Schizophrenia
    • Table 26 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%)
    • Figure 6 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%)
          • Learning Disorders
    • Table 27 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%)
    • Figure 7 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%)
          • Eating Disorders
    • Table 28 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING EATING DISORDERS, 2004 (%)
    • Figure 8 MARKET SHARES OF MANUFACTURERS OF DRUGS TO TREAT EATING DISORDERS, 2004 (%)
          • Conduct Disorders
    • Table 29 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%)
    • Figure 9 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%)
  • MARKET BY DRUG TYPES
      • TOTAL MARKET SIZE
    • Table 30 WORLDWIDE SALES OF DRUGS BY TYPE TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Table 31 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004
    • Figure 10 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 (%)
      • SALES BY TYPE OF THERAPEUTIC CATEGORY
        • BENZODIAZEPINES
    • Table 32 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 11 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
    • Table 33 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 12 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • TRICYCLIC ANTIDEPRESSANTS
    • Table 34 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 13 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • ANTIHISTAMINES
    • Table 35 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 14 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS
    • Table 36 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 15 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • MOOD STABILIZERS
    • Table 37 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 16 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • CNS STIMULANTS
    • Table 38 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 17 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • NONSTIMULANTS
    • Table 39 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 18 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • ATYPICAL ANTIPSYCHOTICS
    • Table 40 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 19 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • MARKET BY DISORDERS
      • TOTAL MARKET SIZE
    • Table 41 WORLDWIDE SALES OF DRUGS BY TYPE OF DISORDER TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Table 42 PERCENTAGE SHARE OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%)
    • Figure 20 SHARES OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%)
      • SALES BY TYPE OF DRUGS
        • ANTIANXIETY AGENTS
    • Table 43 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 21 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • DRUGS USED TO TREAT DEPRESSION
    • Table 44 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 22 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • DRUGS USED TO TREAT BIPOLAR DISORDER
    • Table 45 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 23 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • ADHD DRUGS
    • Table 46 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 24 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • AUTISTIC DISORDER DRUGS
    • Table 47 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 25 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • SCHIZOPHRENIA DRUGS
    • Table 48 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 26 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • DRUGS FOR LEARNING DISORDERS
    • Table 49 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 27 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • DRUGS FOR EATING DISORDERS
    • Table 50 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 28 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • CONDUCT DISORDER DRUGS
    • Table 51 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 29 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • DEMOGRAPHICS
      • OVERVIEW
        • ANTIANXIETY AGENTS
    • Table 52 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 30 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • ANTIDEPRESSANTS
    • Table 53 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 31 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • BIPOLAR DISORDER DRUGS
    • Table 54 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 32 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • ADHD DRUGS
    • Table 55 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 33 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • AUTISTIC DISORDER DRUGS
    • Table 56 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 34 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • SCHIZOPHRENIA DRUGS
    • Table 57 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 35 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • LEARNING DISORDER DRUGS
    • Table 58 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 36 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • EATING DISORDER DRUGS
    • Table 59 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 37 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
        • CONDUCT DISORDER DRUGS
    • Table 60 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
    • Figure 38 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • NEW DEVELOPMENTS
      • NEW DEVELOPMENTS
          • AstraZeneca
    • Table 61 NEW DRUGS FROM ASTRAZENECA
          • Bristol-Myers Squibb
    • Table 62 NEW DRUGS FROM BRISTOL-MYERS SQUIBB
          • Celgene
    • Table 63 NEW DRUGS FROM CELGENE
          • GlaxoSmithKline
    • Table 64 NEW DRUGS FROM GLAXOSMITHKLINE
    • Table 64 (CONTINUED)
          • Johnson & Johnson
    • Table 65 NEW DRUGS FROM JOHNSON & JOHNSON
          • Merck
    • Table 66 NEW DRUGS FROM MERCK
          • Novartis
    • Table 67 NEW DRUGS FROM NOVARTIS
          • Pfizer
    • Table 68 NEW DRUGS FROM PFIZER
          • Roche
    • Table 69 NEW DRUGS FROM ROCHE
          • Sanolfi-Aventis
    • Table 70 NEW DRUGS FROM SANOFI-AVENTIS
          • Shire
    • Table 71 NEW DRUGS FROM SHIRE
          • Solvay
    • Table 72 NEW DRUGS FROM SOLVAY
          • Wyeth
    • Table 73 NEW DRUGS FROM WYETH
  • PATENTS
      • PATENTS BY YEAR
    • Table 74 ANNUAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2001-2005
    • Figure 39 TOTAL PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005
    • Figure 40 ANNUAL SHARE OF PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 (%)
      • PATENTS BY CATEGORY
    • Table 75 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005
    • Figure 41 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005
    • Figure 42 SHARE OF TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 (%)
      • SIGNIFICANT PATENTS OF 2005
    • Table 76 SIGNIFICANT PATENTS FOR DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS, 2005
      • PATENTS BY COMPANY
    • Table 77 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COMPANY, 2001-2005
    • Table 77 (CONTINUED)
      • PATENTS BY COUNTRY
    • Table 78 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS)
    • Table 78 (CONTINUED)
    • Figure 43 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS)
    • Table 79 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2005-2001
    • Figure 44 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005
    • Figure 45 SHARE OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 (%)
      • PATENTS BY ASSIGNEE
    • Table 80 NUMBER AND SHARE OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005
    • Figure 46 NUMBER OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (NUMBER OF PATENTS)
    • Figure 47 SHARES OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (%)
  • INTERNATIONAL ASPECTS
      • TOTAL MARKET SIZE
    • Table 81 REGIONAL SALES OF TREATMENTS FOR BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
      • REGIONAL SALES BY TYPE OF DISORDER
        • ANTIANXIETY AGENTS
    • Table 82 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 48 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • ANTIDEPRESSANTS
    • Table 83 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 49 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • BIPOLAR DISORDER DRUGS
    • Table 84 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 50 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • ADHD DRUGS
    • Table 85 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 51 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • AUTISTIC DISORDER DRUGS
    • Table 86 REGIONAL SALES OF AUTISTIC DISORDER DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 52 REGIONAL SALES OF ADHD DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
        • SCHIZOPHRENIA DRUGS
    • Table 87 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 53 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
          • Learning Disorder Drugs
    • Table 88 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 54 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
          • Conduct Disorder Drugs
    • Table 89 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 55 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
          • Eating Disorder Drugs
    • Table 90 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
    • Figure 56 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
      • PREVELANCE OF EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS IN SELECTED COUNTRIES
        • UNITED STATES
        • UNITED KINGDOM
        • INDIA
        • CHINA
          • China (Continued)
  • COMPANY PROFILES
      • ABBOTT LABORATORIES
      • ALLIANT PHARMACEUTICALS
      • BRISTOL-MYERS SQUIBB
      • CELEGENE
      • CELLTECH PHARMACEUTICALS
      • ELI LILLY
      • GLAXOSMITHKLINE PLC
      • JOHNSON & JOHNSON
      • JOHNSON & JOHNSON (CONTINUED)
      • MALLINCKRODT MEDICAL
      • NOVARTIS PHARMACEUTICAL CORP.
      • OVATION PHARMACEUTICALS
      • PFIZER, INC.
      • ROCHE
      • SHIRE
      • SOLVAY
      • VALEANT PHARMACEUTICALS
  • LIST OF TABLES
  • Summary Table:
  • Table 1 DSM CLASSIFICATIONS* OF EMOTIONAL AND BEHAVIORAL DISORDERS
  • Table 2 CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS (AS DONE FOR THIS REPORT)
  • Table 3 BENZODIAZEPINES
  • Table 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
  • Table 5 TRICYCLIC ANTIDEPRESSANTS
  • Table 6 ANTIHISTAMINES
  • Table 7 MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS
  • Table 8 MOOD STABILIZERS
  • Table 9 CNS STMULANTS
  • Table 10 NONSTMULANTS
  • Table 11 ATYPICAL ANTIPSYCHOTICS
  • Table 12 DRUGS USED FOR ANTIANXIETY DISORDERS
  • Table 13 DRUGS USED FOR SEVERE DEPRESSION
  • Table 14 DRUGS USED FOR BIPOLAR DISORDER
  • Table 15 DRUGS USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER
  • Table 16 DRUGS USED FOR AUTISTIC DISORDER TREATMENT
  • Table 17 DRUGS USED FOR SCHIZOPHRENIA
  • Table 18 LABELLED USE AND APPROVED AGE FOR AGENTS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS
  • Table 19 DRUGS RECEIVING A BOXED WARNING, OTHER PRODUCT LABELING CHANGES, AND A MEDICATION GUIDE PERTAINING TO PEDIATRIC SUICIDAL TENDENCIES
  • Table 20 DEVICES AND IMPLANTS APPROVED BY THE FDA 2000-APRIL 2005
  • Table 21 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
  • Table 22 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
  • Table 23 MARKET SHARES OF MANUFACTURERS PRODUCING DRUGS FOR BIPOLAR DISORDER TREATMENT, 2004 (%)
  • Table 24 MARKET SHARES OF MANUFACTURERS PRODUCING ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
  • Table 25 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%)
  • Table 26 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%)
  • Table 27 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%)
  • Table 28 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING EATING DISORDERS, 2004 (%)
  • Table 29 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%)
  • Table 30 WORLDWIDE SALES OF DRUGS BY TYPE TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 31 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004
  • Table 32 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 33 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 34 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 35 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 36 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 37 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 38 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 39 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 40 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 41 WORLDWIDE SALES OF DRUGS BY TYPE OF DISORDER TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 42 PERCENTAGE SHARE OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%)
  • Table 43 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 44 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 45 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 46 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 47 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 48 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 49 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 50 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010
  • ($ MILLIONS)
  • Table 51 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010
  • ($ MILLIONS)
  • Table 52 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 53 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 54 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 55 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 56 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 57 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 58 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 59 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 60 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Table 61 NEW DRUGS FROM ASTRAZENECA
  • Table 62 NEW DRUGS FROM BRISTOL-MYERS SQUIBB
  • Table 63 NEW DRUGS FROM CELGENE
  • Table 64 NEW DRUGS FROM GLAXOSMITHKLINE
  • Table 65 NEW DRUGS FROM JOHNSON & JOHNSON
  • Table 66 NEW DRUGS FROM MERCK
  • Table 67 NEW DRUGS FROM NOVARTIS
  • Table 68 NEW DRUGS FROM PFIZER
  • Table 69 NEW DRUGS FROM ROCHE
  • Table 70 NEW DRUGS FROM SANOFI-AVENTIS
  • Table 71 NEW DRUGS FROM SHIRE
  • Table 72 NEW DRUGS FROM SOLVAY
  • Table 73 NEW DRUGS FROM WYETH
  • Table 74 ANNUAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2001-2005
  • Table 75 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005
  • Table 76 SIGNIFICANT PATENTS FOR DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS, 2005
  • Table 77 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COMPANY, 2001-2005
  • Table 78 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS)
  • Table 79 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2005-2001
  • Table 80 NUMBER AND SHARE OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005
  • Table 81 REGIONAL SALES OF TREATMENTS FOR BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 82 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 83 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 84 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 85 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 86 REGIONAL SALES OF AUTISTIC DISORDER DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 87 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 88 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 89 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • Table 90 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)
  • LIST OF FIGURES
  • Summary Figure:
  • Figure 1 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
  • Figure 2 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
  • Figure 3 MARKET SHARES OF MANUFACTURERS PRODUCING BIPOLAR DISORDER DRUGS, 2004 (%)
  • Figure 4 MARKET SHARES OF MANUFACTURERS OF ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)
  • Figure 5 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%)
  • Figure 6 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%)
  • Figure 7 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%)
  • Figure 8 MARKET SHARES OF MANUFACTURERS OF DRUGS TO TREAT EATING DISORDERS, 2004 (%)
  • Figure 9 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%)
  • Figure 10 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 11 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 12 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 13 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 14 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 15 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 16 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 17 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 18 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 19 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 20 SHARES OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%)
  • Figure 21 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 22 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 23 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 24 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 25 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 26 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 27 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 28 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 29 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 30 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 31 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 32 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 33 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 34 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 35 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 36 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 37 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 38 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)
  • Figure 39 TOTAL PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005
  • Figure 40 ANNUAL SHARE OF PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 (%)
  • Figure 41 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005
  • Figure 42 SHARE OF TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 (%)
  • Figure 43 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS)
  • Figure 44 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005
  • Figure 45 SHARE OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 (%)
  • Figure 46 NUMBER OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (NUMBER OF PATENTS)
  • Figure 47 SHARES OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (%)
  • Figure 48 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 49 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 50 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 51 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 52 REGIONAL SALES OF ADHD DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 53 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 54 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 55 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
  • Figure 56 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)
概要 原文目次
※この商品は英文にてご提供いたします。
【 英文市場調査報告書 】
児童期／思春期における情緒・行動障害の治療薬市場
Emotional and Behavioral Disorders in Children and Adolescents
出版日 : 2005/09
電話でのお問い合わせ
 この商品について問い合わせる
この商品のサンプル(抜粋)を見る
この商品の閲覧を希望する
価格

※ドル建て価格の商品のお支払いは、為替レート (TTS: 96.31) 換算による円建てのご請求書にて承ります。

US $ 4,543 換算 -> ¥ 437,536 (税抜) Hard Copy
US $ 4,543 換算 -> ¥ 437,536 (税抜) PDF by E-mail (Single User License)

→ご購入方法について

商品コード : 32698
関連カテゴリ : 精神疾患
 関連する商品をキーワードで検索する
FAQ 営業品目 利用規約 サイトマップ
月曜 - 金曜 / 9:30 - 18:30
TEL: 044-952-0102
E-mail: jp-info@gii.co.jp
世界の市場調査資料 総合サイト
© 2008, Global Information, Inc. All rights reserved.